Protibea Therapeutics is looking to raise $11.7 million in a SAFE round, Axios Pro has learned.
Why it matters: The Georgetown, Texas-based developer of neuroinflammation therapies intends to fund its first clinical trial, per managing partner Jim Moriarty.
